Why GLP-1 weight loss platforms struggle to scale without behavioural support

paul sacher • March 10, 2026

Lessons from real world digital health platforms on why behaviour change support becomes critical as GLP-1 services scale.

Most people building GLP-1 services pour their energy into the clinical and operational infrastructure. The prescribing, the compliance, the customer support, getting the medical side to scale. That is genuinely hard work, and it is where most of the pressure concentrates.

Which means the lifestyle and behaviour change layer often gets less focus than it deserves. Not because people think it does not matter, but because there is always something more urgent competing for attention.


Last year my team and I were working with the senior leadership of a very large weight management company. The business was growing fast, with demand accelerating month after month. The operational load had spread across the whole system at once: prescribers reviewing eligibility, patients asked for additional medical information, questions about side effects, dose increases, delivery issues, lifestyle support, and people wanting reassurance that what they were experiencing was normal.


In some of the weight management providers we have worked with across the UK and USA, inbound support volumes have run into the hundreds of thousands of contacts per month. At that scale, pressure stops being an inconvenience and starts becoming a clinical risk.


A question came up in those leadership discussions that I have now heard in several companies.

How much does the surrounding support actually matter?


The medication clearly works. That is why demand exists. But everything around it adds complexity, more teams, more systems, more cost. The argument goes: patients are losing weight, so why invest heavily in lifestyle support now? Focus on medication adherence and side effect management first. Deal with the lifestyle piece later, perhaps when patients start tapering or coming off the drug.


It is a reasonable question, and in the short term the numbers can seem to support it.


The evidence tells a different story. Lifestyle support is not just about behaviour change. It is about preventing muscle and bone loss, avoiding nutritional deficiencies, supporting mental health, and building the habits that sustain weight loss when patients eventually reduce or stop the medication. Without it, much of what the drug achieves can unwind quickly.


The question is not whether to offer lifestyle support. It is when and how to deliver it without overwhelming patients or services.


The real issue is rarely information. It is uncertainty.


People disengage from treatment for many reasons: cost, life circumstances, plateaus, or simply reaching their goal weight. Some take temporary breaks from treatment entirely, sometimes called drug holidays, a period where patients step back from medication, often losing contact with the service at exactly the moment they most need support.


But there is a particular pattern that comes up again and again. Uncertainty builds, patients feel unsupported, and there is no way to resolve that quickly at scale.


In GLP-1 services, that matters more than most platforms realise. Leaders we have worked with have told us that even a one or two percentage point improvement in retention can be worth more than almost any other intervention. The economics compound quickly. When uncertainty goes unaddressed, patient engagement drops and operational pressure rises together.


What we found, working across several of these services, is that many of those moments are predictable. They sit at specific points in the treatment journey: anxiety around the first medication dose, plateau periods, side effect spikes. They are not random. Across the services we have analysed, a significant proportion of inbound support contacts, in some cases over a third, relate to situations that proactive, well timed communication could have addressed before the patient ever needed to reach out.


When the system responds at those moments, sometimes with human support, sometimes automated, patients stay engaged longer and the support burden falls.


The companies getting this right are asking different questions. Not just what support to offer, but when it needs to reach patients, and what it needs to do at that specific point in the treatment journey.


This is the work we do at Sacher AI. We sit at the intersection of behavioural science, applied research, and clinical AI safety, helping health and weight management platforms build AI that is not just technically sound, but behaviourally safe and clinically trustworthy. Designing systems that adapt and respond in the right way at the right moment, from starting treatment through to long term maintenance, is where most of the real work sits.



If any of this reflects what your team is working through, I am happy to have a conversation.

Related blog updates


Diverse digital health team reviewing patient engagement data for a weight management platform
By paul sacher March 12, 2026
GLP-1 drugs are transforming obesity treatment, but behavioural science is lagging. Why digital health platforms may hold the key to better long term outcomes.
Group of people in business attire at a conference table, discussing a presentation displayed on a screen.
March 9, 2026
Reflections from the MHRA AI Airlock simulation workshop
March 9, 2026
Artificial intelligence systems are increasingly interacting directly with people. They guide health decisions. They answer personal questions. They offer advice, reassurance, and encouragement. In many cases they are now embedded in products people use repeatedly over months or even years. Yet most conversations about AI safety still focus almost entirely on technical performance. Accuracy, bias, privacy, and security dominate the discussion. These are essential considerations. But they are not the whole story. What is still missing in many AI systems is systematic evaluation of behavioural impact. A global call from behavioural scientists Recently, Dr Paul Sacher, Founder of Sacher AI and Research Director at the Behavioral AI Institute, led an international group of behavioural scientists to address this issue. Their open letter, now published in Wellcome Open Research, argues that artificial intelligence systems inevitably influence how people think, feel, decide, and act. Despite this, behavioural effects are rarely treated as a core requirement in AI development, evaluation, or governance. The paper brings together researchers from institutions including Imperial College London, Harvard University, Duke University, the University of Exeter, and the Alan Turing Institute. It outlines where behavioural risks arise in real world AI systems and why these risks deserve far greater attention. Behavioural risks are not edge cases When organisations think about AI risk, they often focus on incorrect outputs or technical failures. However, behavioural risks can emerge even when systems are technically accurate. AI systems influence behaviour through repeated interaction. They shape decision making, motivation, confidence, and emotional responses over time. For example, conversational systems can unintentionally: · encourage over reliance on automated advice · reinforce existing beliefs through personalisation · influence emotional regulation through tone and framing · alter motivation and goal setting behaviour · reduce appropriate help seeking in certain contexts These effects arise through well documented behavioural mechanisms such as automation bias, trust calibration, anthropomorphism, and reinforcement learning from user feedback. Yet most AI evaluation frameworks still prioritise task success and user satisfaction rather than behavioural outcomes. The growing gap between technical success and real world impact This creates a gap between technical performance and real world impact. A system can perform well on benchmarks and still shape behaviour in ways that undermine user wellbeing, decision quality, or long term outcomes. The risk becomes particularly important in domains where AI systems interact with people repeatedly and at scale. Healthcare, education, financial guidance, and emotional support tools are clear examples. In these environments, small behavioural effects can accumulate over time and remain invisible to standard performance metrics. Behavioural science is often missing from the AI lifecycle Behavioural science offers decades of research into how people think, feel, and act. It provides practical tools for understanding trust, influence, decision making, and motivation. However, behavioural expertise is still rarely embedded systematically across the AI lifecycle. In many projects behavioural scientists are not involved in system design, consulted only during ethics review, or brought in late in development when major design choices are already fixed. This often means behavioural risks are identified too late or not assessed at all. What responsible AI should look like The open letter argues that responsible AI must go beyond technical safeguards. Systems that interact directly with people must demonstrate what the authors describe as psychological competence. In practice, this means responding in ways that are emotionally appropriate, behaviourally responsible, and aligned with the user’s needs and context. Achieving this requires several shifts in how AI systems are designed and evaluated. Behavioural assumptions should be made explicit during design. Behavioural expertise should be embedded early in development. Evaluation should assess behavioural outcomes alongside technical performance. Monitoring should continue after deployment as systems evolve and users adapt. These are not theoretical concerns. They are practical requirements for building AI systems that work safely in real world environments. Why this matters for digital health and AI companies At Sacher AI we see this challenge frequently when working with digital health companies building patient facing AI systems. Teams often focus heavily on model performance, prompt design, or system architecture. These are important elements. But once systems begin interacting with people, behavioural dynamics quickly become central to product safety and effectiveness. Tone influences trust. Feedback influences motivation. Personalisation influences decision making. Without deliberate behavioural evaluation, systems can unintentionally nudge users in directions that product teams never intended. For companies operating in regulated environments such as healthcare, this also has implications for governance, compliance, and long term product risk. Bringing behavioural safety into AI development Addressing behavioural risk does not require reinventing AI governance. It requires integrating behavioural science into existing development processes. In practice this can include structured behavioural evaluation during development, adversarial testing of conversational agents, governance frameworks for human facing AI, and ongoing monitoring of behavioural outcomes once systems are deployed. Many organisations are beginning to recognise this gap and are looking for ways to assess behavioural safety earlier in their development pipeline. A broader shift in how we think about AI safety The central message of the open letter is simple. If AI systems influence human behaviour, behavioural science must be treated as foundational infrastructure for responsible AI. Technical safety alone is not enough. Understanding how people interpret, trust, and respond to AI systems is essential for building technology that works safely and effectively in the real world. Read the open letter The full paper is available in Wellcome Open Research . About Sacher AI Sacher AI works with digital health and AI companies to design, test, and deploy human facing AI systems safely and effectively. Our work combines behavioural science, AI engineering, and real world healthcare experience to help organisations build AI systems that are not only technically strong but also clinically and behaviourally safe.  If your organisation is developing AI systems that interact directly with patients or users, we are always happy to start a conversation. More information can be found at https://sacher.ai Sacher PM, Michie S, Hauser OP et al. The missing discipline in AI: a call for behavioural science . Wellcome Open Res 2026, 11:152 (https://doi.org/10.12688/wellcomeopenres.25922.1)